Latest news with #iTeosTherapeutics
Globe and Mail
a day ago
- Business
- Globe and Mail
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of iTeos Therapeutics, Inc. (NasdaqGM: ITOS) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of iTeos will receive $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain iTeos' product candidates that occurs within six months following the closing. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Associated Press
2 days ago
- Business
- Associated Press
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iTeos Therapeutics, Inc. (NASDAQ: ITOS)'s sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing. If you are an iTeos shareholder, click here to learn more about your rights and options. ZimVie Inc. (NASDAQ: ZIMV)'s sale to an affiliate of ARCHIMED for $19.00 in cash per share. If you are a ZimVie shareholder, click here to learn more about your rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. One World Trade Center 85th Floor New York, NY 10007 (212) 763-0060 [email protected] [email protected]
Globe and Mail
2 days ago
- Business
- Globe and Mail
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iTeos Therapeutics, Inc. (NASDAQ: ITOS) to Concentra Biosciences, LLC is fair to iTeos shareholders. Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing. Halper Sadeh encourages iTeos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether iTeos and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for iTeos shareholders; (2) determine whether Concentra is underpaying for iTeos; and (3) disclose all material information necessary for iTeos shareholders to adequately assess and value the merger consideration. On behalf of iTeos shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
08-07-2025
- Business
- Yahoo
iTeos Therapeutics (ITOS): An Example of Biotech Liquidations
LVS Advisory, a New York City-based full-service investment firm, recently released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first half of 2025, the LVS Event-Driven portfolio returned 3.6% (net of fees), and the LVS Growth Portfolio delivered 15.8% net of all fees and expenses. This compares to a 4.8% return for the high-yield bond index and a 6.2% gain for the S&P 500 index. For more information on the fund's top picks in 2025, please check its top five holdings. In its second quarter 2025 investor letter, LVS Advisory highlighted stocks such as iTeos Therapeutics, Inc. (NASDAQ:ITOS). iTeos Therapeutics, Inc. (NASDAQ:ITOS) is a clinical-stage biopharmaceutical company. The one-month return of iTeos Therapeutics, Inc. (NASDAQ:ITOS) was -0.40%, and its shares lost 33.36% of their value over the last 52 weeks. On July 7, 2025, iTeos Therapeutics, Inc. (NASDAQ:ITOS) stock closed at $10.07 per share, with a market capitalization of $385.417 million. LVS Advisory stated the following regarding iTeos Therapeutics, Inc. (NASDAQ:ITOS) in its second quarter 2025 investor letter: "On May 13, 2025, iTeos Therapeutics, Inc. (NASDAQ:ITOS) announced poor results from its Clinical Phase 2 study for its leading drug candidate. The Company announced it would terminate the program and initiate a review of 'strategic alternatives to maximize shareholder value'. At the time of that announcement, ITOS stock traded for $7.60 per share and had $12 per share of cash on its balance sheet (net of liabilities). On the heels of this news, we purchased shares for ~$7.71 on average. A medical professional demonstrating a drug delivery process with the help of animated graphics, highlighting the ADCC activity of the company. ITeos Therapeutics, Inc. (NASDAQ:iTOS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held iTeos Therapeutics, Inc. (NASDAQ:ITOS) at the end of the first quarter, compared to 31 in the previous quarter. While we acknowledge the potential of iTeos Therapeutics, Inc. (NASDAQ:ITOS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of ITOS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
19-04-2025
- Business
- Yahoo
Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year
Given the large stake in the stock by institutions, iTeos Therapeutics' stock price might be vulnerable to their trading decisions The top 11 shareholders own 51% of the company Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company We check all companies for important risks. See what we found for iTeos Therapeutics in our free report. If you want to know who really controls iTeos Therapeutics, Inc. (NASDAQ:ITOS), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are institutions with 64% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Institutional investors would probably welcome last week's 15% increase in the share price after a year of 38% losses as a sign that returns may to begin trending higher. Let's take a closer look to see what the different types of shareholders can tell us about iTeos Therapeutics. Check out our latest analysis for iTeos Therapeutics Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. iTeos Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at iTeos Therapeutics' earnings history below. Of course, the future is what really matters. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 6.1% of iTeos Therapeutics shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Looking at our data, we can see that the largest shareholder is MPM BioImpact LLC with 12% of shares outstanding. The second and third largest shareholders are BlackRock, Inc. and BVF Partners L.P., with an equal amount of shares to their name at 6.1%. Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 11 shareholders, meaning that no single shareholder has a majority interest in the ownership. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our data suggests that insiders own under 1% of iTeos Therapeutics, Inc. in their own names. It seems the board members have no more than US$942k worth of shares in the US$249m company. Many tend to prefer to see a board with bigger shareholdings. A good next step might be to take a look at this free summary of insider buying and selling. With a 13% ownership, the general public, mostly comprising of individual investors, have some degree of sway over iTeos Therapeutics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. With an ownership of 17%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere. While it is well worth considering the different groups that own a company, there are other factors that are even more important. Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
